An Act Requiring Health Insurance Coverage For Biomarker Testing.
Summary
SB 554 would amend Connecticut’s insurance statutes to require both individual and group health insurance policies to cover biomarker testing. The bill is framed as a coverage mandate, meaning insurers would be required to pay for biomarker testing when provided under the policy terms and applicable medical standards. The text does not specify detailed eligibility criteria, utilization controls, or reimbursement rules, leaving those implementation details to the insurance framework and any future regulatory guidance.
In practical terms, the bill would expand access to biomarker testing for insured patients by making it a covered benefit in health plans subject to chapter 700c of the general statutes. Biomarker testing is commonly used to help diagnose conditions, guide treatment selection, and monitor disease progression, particularly in areas such as cancer care and precision medicine. If enacted, the measure would affect health insurers, policyholders, and providers by shifting the cost of covered testing from patients to insurers.
Impact
The bill would modify chapter 700c of the Connecticut General Statutes to add a new insurance coverage requirement for biomarker testing. This would directly affect individual and group health insurance policies regulated under state law, likely increasing covered benefits and potentially affecting premiums, plan design, and claims administration. Health insurers would need to update coverage policies and billing practices, while patients and providers would gain broader access to testing without relying solely on out-of-pocket payment.
Sentiment
There is no recorded committee transcript or vote history in the provided materials, so the bill’s sentiment cannot be measured from debate or roll call data. Based on the bill’s purpose and structure, it appears to be a health coverage expansion intended to improve access to medically relevant testing. The absence of recorded opposition or amendments in the provided context suggests the measure was at least introduced in a straightforward, policy-focused manner.
Contention
No specific points of contention are documented in the provided committee materials. In a bill of this type, likely areas of debate would include whether biomarker testing should be mandated for all plans, how broadly the term should be defined, and whether coverage should be limited to tests supported by clinical evidence or tied to particular diagnoses. Potential stakeholders with differing views would include patient advocates and medical providers favoring broader coverage, and insurers concerned about cost, utilization, and mandate expansion.